FRI0316 The Efficacy and Safety of Subcutaneous Tocilizumab versus Intravenous Tocilizumab in Combination with Traditional DMARDS in Patients with RA at Week 97 (SUMMACTA)

Background Tocilizumab (TCZ) is approved as an intravenous (IV) formulation globally and subcutaneous (SC) formulation in the US for the treatment of adult rheumatoid arthritis (RA). In the SUMMACTA study, efficacy and safety of TCZ-SC weekly (qw) was demonstrated through week (wk) 24 in patients (p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.499-500
Hauptverfasser:	Burmester, G., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D., Rangaraj, M.J., Roane, G., Ludivico, C., Mysler, E., Bennett, M.J., Rowell, L., Bao, M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!